Diaphragmatic Work During HFNC and CPAP Support

Respiratory Insufficiency in Children Clinical Trial

— DiaWorkHFNC  

Official title:

Impact of Increasing Flow Rates in High-flow Nasal Cannula and CPAP on Diaphragmatic Work in Newborn and Paediatric Population: Non-inferiority Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06249009
• Other study ID #: AOI 2022 SAVY
• Status: Recruiting
• Phase: N/A
• Start date: November 27, 2023
• Est. completion date: November 27, 2025

Study information

• Verified date: June 2023
• Source: University Hospital, Clermont-Ferrand
• Contact: Lise Laclautre
• Phone: 334.73.754.963
• Email: promo_interne_drci[@]chu-clermontferrand.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this randomised controlled, cross-over clinical trial is to compare High Flow Nasal Cannulas (HFNC) and Continuous Positive Airways Pressure (CPAP) in neonates over 34 weeks' amenorrhoea (SA) up to children weighing less than 20 kg with respiratory failure.

The main question it aims to answer is the non-inferiority of high flows of high-flow nasal cannula compared with CPAP by analysis of diaphragmatic contraction (EAdi (Electrical activity of diaphragm)).

Participants with respiratory failure and need of non invasive ventilation and nasogastric tube will receive 4 different increasing flows of HFNC and Positive End-Expiratory Pressure of 7 cmH2O with CPAP during 30 minutes for each flow rate and CPAP. The electrical activity of diaphragm and clinical data of the patient upon each flow and support will be collected. According to the cross-over procedure, the patients will change groups (increasing flows of HFNC or CPAP) in order to perform the remaining analysis.

Description:

With this research protocol, the investigators aim to demonstrate the non-inferiority of high flows of HFNC compared with CPAP on work of breathing (based on the intensity of contraction of diaphragmatic fibres and clinical aspects) in paediatric and neonatal patients. The investigators will also study the clinical tolerance and safety of these practices.

Objectives :

Main objective: To demonstrate the non-inferiority of high-flow nasal cannula flow rates compared with CPAP by analysis of diaphragmatic contraction (EAdi (Electrical activity of diaphragm)) in neonates over 34 weeks' amenorrhoea (SA) up to children weighing less than 20 kg in respiratory failure.

Secondary objectives:

• To compare different flows of HFNC (2 L/kg/min, 3 L/kg/min, 4 L/kg/min, 5 L/kg/min) with each other by analysing diaphragmatic contraction.

• Compare the clinical effectiveness of different flow rates of HFNC with CPAP in young children in respiratory distress.

• To compare the tolerability of different flow rates of HFNC with CPAP in the population of young children suffering from respiratory distress.

• To compare the incidence of minor (digestive discomfort, digestive bloating, non-damaging skin lesions) and major (thoracic barotrauma, damaging skin lesions) side effects of different flow rates of HFNC with CPAP in young children in respiratory distress.

• To describe the choice of support and settings (flow rates or PEEP levels) made by the practitioners in charge of the child after the study period.

• To describe the epidemiological data from the paediatric intensive care and monitoring units and the neonatal intensive care unit.

Type of study: Randomised controlled, cross-over, single-centre, non-inferiority trial of a medical device.

Number of centres: 1

Study design:

Upon admission to the department, if the eligibility criteria are met and the parents agree to the research , a wash-out period will be performed under low-flow oxygen therapy at 1 L/min to achieve SpO2 ≥ 94% for 15 minutes.

The included patients will then be randomized into two separate groups: a CPAP group with PEEP at 7 cmH2O for 30 minutes and an HFNC group with increasing flow rates for up to 2 hours.

The patients included will be their own controls and at the end of the first analysis, according to the cross-over procedure, the patients will change groups in order to perform the remaining analysis.

A recourse procedure has been foreseen in case of failure of ventilatory support.

Medical devices :

Concerning HFNC ventilation:

The nasal cannulas used are Optiflow® cannulas (Fisher and Paykel Laboratory) which will be adapted to the size of each patient's nostrils. The following sizes are available:

• NICU patient: Optiflow Junior 2®.

• PICU patient: Optiflow Junior 2®, Optiflow +®.

Concerning CPAP ventilation:

• For the neonatal population:

• Medin Sindi® CPAP masks, caps and ties

• Medin Miniflow® CPAP generators

• For the paediatric population :

• Medin Sindi® CPAP masks, caps and ties

• Fisher and Paykel Healthcare CPAP masks, cannulas and caps

• Miniflow® CPAP generators from Medin

• Fisher and Paykel Healthcare CPAP generators

Expected benefits :

If it is shown that a reduction in the work of breathing is observed (EAdi and usual clinical signs) when HFNC flow rates are gradually increased, and that this increase to flow rates of 3 to 5 L/kg/min is well tolerated and does not increase the risk of barotrauma, HFNC ventilation at flow rates greater than 2 L/kg/min could be more widely proposed and accepted in the various units using it, as it is unanimously accepted in terms of tolerance and comfort for the patient compared with CPAP.

Recruitment procedures The patients eligible for this study will be those admitted to the neonatal and paediatric intensive care unit of the Clermont-Ferrand University Hospital by a doctor on the unit and who meet the various inclusion criteria for the study.

An information note has been drawn up and will be presented and explained to the child's legal representative(s) by an investigating doctor during their usual care, as well as to the child if his or her level of understanding is adequate, within 2 hours of admission to the department. The parents and the child will have a maximum of 1 hour to reflect (and a maximum of 3 hours from admission to the ward) between the time they are given the information and the time they sign the consent form.

Legal representative(s) will then be asked to sign the written consent. The child's inclusion in the DiaworkHFNC protocol will be recorded in the child's computerised medical record (ICCA software).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 80
• Est. completion date: November 27, 2025
• Est. primary completion date: November 27, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 34 Weeks to 6 Years

Eligibility

Inclusion Criteria:

• Newborns over 34 SA and paediatric patients weighing less than 20 kg.

• Need for ventilatory support by HFNC or CPAP for respiratory failure

• Need for enteral feeding via nasogastric tube

• Hospitalized in PICU or NICU at Clermont-Ferrand University Hospital,

• Covered by Social Security.

• Whose parents or guardians are able to provide informed consent to participate in the research.

Exclusion Criteria:

• Respiratory failure requiring immediate intubation.

• Use of HFNC or CPAP as a relay to extubation.

• Acquired or congenital abnormality of the gastrointestinal tract.

• Diaphragmatic paralysis and/or neuromuscular pathology

• Failure of central ventilatory control (e.g. intra-ventricular haemorrhage, anoxic-ischaemic encephalopathy, massive vascular accident, intracranial process, cerebral edema and/or intracranial hypertension).

• Contraindications listed in the CPAP and HFNC user manuals: absence of spontaneous ventilation, choanal atresia, diaphragmatic hernia, tracheo-oesophageal fistula, nasal trauma, severe deformity likely to be aggravated by the nasal mask or nasal cannula, pneumothorax, pneumencephaly, Cerebrospinal Fluid leak, hypotension.

• Refusal by parents or guardians.

Related Conditions & MeSH terms

• CPAP Ventilation
• Newborn Rds
• Respiratory Insufficiency
• Respiratory Insufficiency in Children

Intervention

Device:
• Non invasive ventilation
CPAP and increasing flows of HFNC will be compared during a 30-minutes period each

Locations

Country	Name	City	State
France	CHU Clermont-Ferrand	Clermont-Ferrand

Sponsors (3)

Lead Sponsor	Collaborator
University Hospital, Clermont-Ferrand	Fisher and Paykel Healthcare, Maquet Critical Care AB

Country where clinical trial is conducted

France, 

References & Publications (5)

Milesi C, Essouri S, Pouyau R, Liet JM, Afanetti M, Portefaix A, Baleine J, Durand S, Combes C, Douillard A, Cambonie G; Groupe Francophone de Reanimation et d'Urgences Pediatriques (GFRUP). High flow nasal cannula (HFNC) versus nasal continuous positive — View Citation

Milesi C, Pierre AF, Deho A, Pouyau R, Liet JM, Guillot C, Guilbert AS, Rambaud J, Millet A, Afanetti M, Guichoux J, Genuini M, Mansir T, Bergounioux J, Michel F, Marcoux MO, Baleine J, Durand S, Durand P, Dauger S, Javouhey E, Leteurtre S, Brissaud O, Re — View Citation

Nasef N, El-Gouhary E, Schurr P, Reilly M, Beck J, Dunn M, Ng E. High-flow nasal cannulae are associated with increased diaphragm activation compared with nasal continuous positive airway pressure in preterm infants. Acta Paediatr. 2015 Aug;104(8):e337-43 — View Citation

Pham TM, O'Malley L, Mayfield S, Martin S, Schibler A. The effect of high flow nasal cannula therapy on the work of breathing in infants with bronchiolitis. Pediatr Pulmonol. 2015 Jul;50(7):713-20. doi: 10.1002/ppul.23060. Epub 2014 May 21. — View Citation

Ramnarayan P, Richards-Belle A, Drikite L, Saull M, Orzechowska I, Darnell R, Sadique Z, Lester J, Morris KP, Tume LN, Davis PJ, Peters MJ, Feltbower RG, Grieve R, Thomas K, Mouncey PR, Harrison DA, Rowan KM; FIRST-ABC Step-Up RCT Investigators and the Paediatric Critical Care Society Study Group. Effect of High-Flow Nasal Cannula Therapy vs Continuous Positive Airway Pressure Therapy on Liberation From Respiratory Support in Acutely Ill Children Admitted to Pediatric Critical Care Units: A Randomized Clinical Trial. JAMA. 2022 Jul 12;328(2):162-172. doi: 10.1001/jama.2022.9615. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Variations of mean max electrical activity of the diaphragm (mean EAdi) between different HFNC flows and between each HFNC flow and CPAP	Maximal EAdi will be measured in µV	Maximal electrical activity of diaphragm will be recorded every minutes (up to 3 hours)
Secondary	Variation in mean minimum EAdi (EAdi min) between different HFNC flows and between each HFNC flow and CPAP	Minimum EAdi will be measured in µV	Minimal electrical activity of diaphragm will be recorded every minutes (up to 3 hours)
Secondary	Variations of heart rate between the different rates of HFNC and between each rate of HFNC and CPAP	Heart rate will be measured in beats per minute (bpm)	every 5 minutes during 3 hours
Secondary	Variations of respiratory rate between the different rates of HFNC and between each rate of HFNC and CPAP	Respiratory rate will be measured in breath per minute	every 5 minutes during 3 hours
Secondary	Variations of oxygen saturation between the different rates of HFNC and between each rate of HFNC and CPAP	Oxygen saturation will be measured in percentage	every 5 minutes during 3 hours
Secondary	Variations of transcutaneous partial pressure of carbon dioxide between the different rates of HFNC and between each rate of HFNC and CPAP	Transcutaneous partial pressure of carbon dioxide will be measured in mmHg	every 5 minutes during 3 hours
Secondary	Variations of respiratory distress score between the different rates of HFNC and between each rate of HFNC and CPAP	score of Silverman (0 to 10), or score modified Wood score (0 to 10) or score of PRAM (0 to 12) depending on the pathology	Every 30 minutes during 3 hours
Secondary	Incidence of minor side effects for each HFNC flow rate and for CPAP	bloating and/or gastrointestinal discomfort with no other associated cause, low-grade skin trauma	Every 30 minutes during 3 hours
Secondary	Incidence of major side effects for each flow of HFNC and for CPAP	Barotrauma to the chest, pneumothorax or pneumomediastinum; Bradycardia defined as : if < 1 year: Heart rate (HR) < 100 bpm for 20 seconds or < 60 bpm for 5 seconds if = 1 year: HR < 100 bpm for 20 seconds or < 40 bpm for 5 seconds Number of desaturations (oxygen saturation rate (SpO2) < 88% for 3s), apneas (breathing pause = 10s) High-grade skin trauma	Every 30 minutes during 3 hours
Secondary	Intubation rate		through patient follow-up period, up to 3 hours
Secondary	Ventilatory weaning time	Weaning from all types of pressure support	From date of randomization until the date of pressure weaning support, up to 30 days.